- Creso Pharma (CPH) has successfully delivered the second shipment of cannaQIX products to Pharma Dynamics South Africa
- Pharma Dynamics is a subsidiary of Lupin International which is the fifth largest pharmaceutical company in South Africa
- This delivery saw Creso Pharma pocket CHF220,000 (around A$320,000) which has already been added to the company’s growing revenue portfolio
- cannaQIX is Creso Pharma’s range of cannabidiol oil-based nutraceuticals which aim to improve stress management and support mental health
- Shares in CPH are up 3.26 per cent on the back of this news and are trading at 23.8 cents
Creso Pharma (CPH) has successfully delivered the second shipment of cannaQIX products to Pharma Dynamics South Africa.
Pharma Dynamics is a subsidiary of Lupin Internationa,l which is the fifth-largest pharmaceutical company in South Africa.
Currently, it distributes Creso Pharma’s products across South Africa but has plans to extend it throughout Namibia, Lesotho, Mozambique, Zimbabwe, Botswana, Uganda, Angola and Swaziland.
This delivery saw Creso Pharma pocket CHF220,000 (around A$320,000) which has been added to the company’s growing revenue portfolio.
“We are excited about the completion of this second order from Pharma Dynamics which has underpinned a very successful launch of cannaQIX under the Cannamics brand in South Africa,” Commercial Director Jorge Wernli said.
“We are very proud of having accomplished this delivery in spite of the current restrictions in place, mainly due to the COVID situation. We are looking forward to further growth throughout South Africa and other territories together with Pharma Dynamics,” he addd.
cannaQIX is Creso Pharma’s range of cannabidiol oil-based nutraceuticals, which aim to improve stress management and support mental health and nervous functions.
Creso Pharma is now working on a number of new opportunities and partnerships which will be announced in due course.
Shares in CPH are up 3.26 per cent on the back of this news and are trading at 23.8 cents at 1:52 pm AEDT.